Technical Analysis for CNST - Constellation Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 11.93 5.20% 0.59
CNST closed up 5.2 percent on Friday, February 15, 2019, on 1.2 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Up
See historical CNST trend table...

Date Alert Name Type % Chg
Feb 15 New 52 Week Closing High Bullish 0.00%
Feb 15 Earnings Movers Other 0.00%
Feb 15 Inside Day Range Contraction 0.00%
Feb 15 Wide Bands Range Expansion 0.00%
Feb 15 Overbought Stochastic Strength 0.00%
Feb 14 Slingshot Bullish Bullish Swing Setup 5.20%
Feb 14 Volume Surge Other 5.20%
Feb 14 Calm After Storm Range Contraction 5.20%
Feb 14 Wide Range Bar Range Expansion 5.20%
Feb 14 New 52 Week High Strength 5.20%

Older signals for CNST ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Constellation Pharmaceuticals, Inc. is a United States-based company, which discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The Company has two clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, and the other program is evaluating a compound, CPI-1205. CPI-0610 is a small molecule that inhibits the binding of bromodomain and extra terminal (BET) proteins to chromatin. CPI-1205 is a small molecule that inhibits an enzyme, Enhancer of Zeste Homolog 2 (EZH2). It is in a Phase I clinical study of CPI-0610 in patients with progressive lymphoma; a Phase I clinical study of CPI-0610 in patients with acute leukemia, myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasms; a Phase I clinical study of CPI-0610 in patients with previously treated multiple myeloma, and a Phase 1 clinical study of CPI-1205 in patients with lymphoma.
Cancer Diseases Treatment Of Cancer Lymphoma Multiple Myeloma Myelodysplastic Syndrome Acute Leukemia Ezh2 Myeloproliferative Neoplasm
Is CNST a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.45
52 Week Low 4.005
Average Volume 39,759
200-Day Moving Average 0.0
50-Day Moving Average 6.7546
20-Day Moving Average 8.36
10-Day Moving Average 10.046
Average True Range 0.9384
ADX 41.31
+DI 36.6051
-DI 5.3103
Chandelier Exit (Long, 3 ATRs ) 9.6348
Chandelier Exit (Short, 3 ATRs ) 7.9752
Upper Bollinger Band 12.0985
Lower Bollinger Band 4.6215
Percent B (%b) 0.98
BandWidth 89.437799
MACD Line 1.3541
MACD Signal Line 0.9895
MACD Histogram 0.3646
Fundamentals Value
Market Cap 21.17 Million
Num Shares 1.77 Million
EPS -49.87
Price-to-Earnings (P/E) Ratio -0.24
Price-to-Sales 0.00
Price-to-Book 0.23
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.08
Resistance 3 (R3) 13.84 12.88 13.72
Resistance 2 (R2) 12.88 12.34 13.00 13.60
Resistance 1 (R1) 12.41 12.00 12.65 12.65 13.48
Pivot Point 11.45 11.45 11.57 11.57 11.45
Support 1 (S1) 10.98 10.91 11.22 11.22 10.38
Support 2 (S2) 10.02 10.57 10.14 10.26
Support 3 (S3) 9.55 10.02 10.14
Support 4 (S4) 9.79